Table 1.
Phase III trials comparing EGFR inhibitors to chemotherapy in first-line treatment.
| Study | Treatment Arms | mPFS (Months) | mOS (Months) | ORR (%) | Ref. |
|---|---|---|---|---|---|
| IPASS | Gefitinib vs. carboplatin/paclitaxel | 9.8 vs. 6.4 p < 0.001 |
21.6 vs. 21.9 p = 0.99 |
71.2 vs. 47.3 | [15] |
| NEJ002 | Gefitinib vs. carboplatin/paclitaxel | 10.8 vs. 5.4 p < 0.001 |
27.7 vs. 26.6 p = 0.48 |
73.7 vs. 30.7 | [13] |
| WJT0G3405 | Gefitinib vs. cisplatin/docetaxel | 9.2 vs. 6.3 p < 0.0001 |
36.0 vs. 39.0 | 62.1 vs. 32.2 | [16] |
| OPTIMAL | Erlotinib vs. carboplatin/gemcitabine | 13.1 vs. 4.6 p < 0.0001 |
22.8 vs. 27.2 p = 0.27 |
83.0 vs. 36.0 | [17] |
| EURTAC | Erlotinib vs. cisplatin/docetaxel | 9.7 vs. 5.2 p < 0.0001 |
19.3 vs. 19.5 p = 0.87 |
64.0 vs. 18.0 | [18] |
| ENSURE | Erlotinib vs. cisplatin/gemcitabine | 11 vs. 5.6 | 26.3 vs. 25.5 | 62.7 vs. 33.6 | [20] |
| CONVINCE | Icotinib vs. cisplatin/pemetrexed | 11.2 vs. 7.9 p = 0.006 |
30.5 vs. 32.1 p = 0.89 |
NR | [21] |
| LUX-Lung 3 | Afatinib vs. cisplatin/Pemetrexed | 11.1 vs. 6.9 p = 0.001 |
28.2 vs. 28.2 p = 0.39 |
56.1 vs. 22.6 | [22] |
| LUX-Lung 6 | Afatinib vs. cisplatin/gemcitabine | 11.0 vs. 5.6 p < 0.0001 |
23.1 vs. 23.5 p = 0.61 |
66.9 vs. 23.0 | [23] |
| AURA 3 | Osimertinib vs. platinum/pemetrexed | 10.1 vs. 4.4 p < 0.001 |
NA | 26.8 vs. 22.5 | [24] |
| CTONG | Erlotinib vs. gefitinib | 13.2 vs. 11.1 | 22.4 vs. 20.7 | NR | [25] |
| LUX-Lung 7 | Afatinib vs. gefitinib | 13.7 vs. 11.5 p = 0.007 |
27.9 vs. 24.5 | 70 vs. 56 | [26] |
| FLAURA | Osimertinib vs. erlotinib or gefitinib | 18.9 vs. 10.2 p < 0.001 |
NR | 80.0 vs. 76 | [27] |
mPFS: median Progression-Free Survival. mOS: median Overall Survival. ORR: Objective Response Rate. NR: Not Reported.